Clik here to view.
Pharma: positive change in 2013
Stay long: SAN, ROG, GSK, NOVOB, COLOB, FRE, FME The FDA to remove red-tape of approval process… Things have gone quiet on this, but we expect that changes as we enter 2013. Top officials at the FDA...
View ArticleGlobesity: “Diabetes is a global crisis that no population or country can...
“…and the unmet needs are considerable”. J&J’s CEO, yesterday. Given the explosion in ‘Globesity’ this unfortunate growth industry in Healthcare has significant long term drivers ahead. As such...
View ArticleClik here to view.
Sterling has fallen 10% vs. the EUR since July
Stay long GSK. Europe is their second biggest market.
View ArticleGlaxoSmithKline (aviate HQGB): “Could the best play on Reflation/weak...
Further to our recent comments on the beneficiaries of a weak Sterling, we today turn to GlaxoSmithKline. From last year: “Could the best play on Reflation/weak sterling retire equity?” If you truly...
View ArticleGlaxoSmithKline (HQGB): positive data on key pipeline drug. Add
We have highlighted the strong pipeline and differentiated R&D approach at GlaxoSmithKline before. Positive phase III data on their HIV drug dolutegravir today, strengthens the likelihood of...
View ArticleClik here to view.
GlaxoSmithKline (HQGB): “If you don’t buy them, they will”
Last night GlaxoSmithKline raised 3 year money at 0.7%. Its WACD is 2.3%. Its dividend yield is 5.2%. So, they could buy their own equity, gear themselves into reflation/’the great rotation’ and...
View ArticleClik here to view.
Yield is still scarce
A rated corporate rated debt in Europe is back to 1.6%, close to a record low. BBB rated bonds are back to all-time lows of 2.8%. The High Yield ETF is near an all-time high in the US. T-Bills are just...
View ArticleGlaxoSmithKline & Roche (HQGB): treatments effective against new Bird Flu...
The new strain of bird flu that has emerged in Eastern China killed a third person, as the World Health Organization said the new virus is sensitive to Roche’s Tamiflu and GlaxoSmithKline’s Relenza...
View ArticleGlaxoSmithKline & Roche: Bird flu (cont), what happened last time
The H5NI (SARS) virus killed 260 people worldwide. The Swine Flu (H1N1 virus) outbreak, which took hold in 2009, killed nearly 300,000 people. The 2009 H1N1 swine flu originated as a mix of bird,...
View ArticleClik here to view.
Pharma/Med Tech and a return to the 1990s
We can’t help but note the price action in the US. TMO is a $30bn med-tech company. Yesterday it bid for LIFE at a 12% premium. No surprise to see the latter up 8% to an all-time high. What is...
View ArticleClik here to view.
Magnificent 7: HQG + ‘Bond like equities’
When we ask those CIOs with Bond-market backgrounds what they look for in Equities, they say the following: i) bond-like duration (think Buffett 10 year test) ii) bond-like volatility (think low...
View ArticleGlaxoSmithKline & Roche: ‘Bird Flu’, notable change in tone
Notable change in tone from the official Xinhua news agency. The authorities now admit the source of the H7N9 infection has not been effectively controlled. As such, the number of cases of infections...
View ArticleGlaxoSmithKline, refer the last Pharma bull market for clues
In the last Pharma bull market, GSK 3-bagged. It has only doubled since 2005 and the context then, as now is similar. Will history rhyme? It already is. Just adding Breo to GSK’s sales, takes 2018...
View ArticlePharma, a reminder of the 1990s
Last year we highlighted a White House plan to double the number of new prescription drugs that go on the market each year by more quickly approving drugs to treat high-risk patients. The plan, aimed...
View ArticleGlaxoSmithKline (HQGB): pioneering R&D
GSK will partner with venture capitalists (Avalon Ventures) in a first of a kind deal to seed funding and payments to multiple drug discovery firms to explore promising targets for drugs. With small...
View ArticleClik here to view.
Cancer, a terrifying projection
Apparently Varian forecast that by 2020 that there will be more Chinese suffering from lung cancer – than ALL the cancer suffers (of all types) in the rest of the world put together. Whilst terribly...
View ArticleDe-equitisation: if you don’t buy stock, they will
GlaxoSmithKline, to name just one, has been doing it for years. Namely, they sell their debt cheap to fund the equity. Apple followed suit yesterday, the $17billion bonds sold representing the largest...
View ArticleGlaxoSmithKline (HQGB): embracing technology
Yesterday GlaxoSmithKline launched a new data platform which will allow independent experts to assess clinical trials. The ‘open innovation’ platform is the first of its type among peers. It can...
View ArticleGlaxoSmithKline (HQGB): embracing technology
Yesterday GlaxoSmithKline launched a new data platform which will allow independent experts to assess clinical trials. The ‘open innovation’ platform is the first of its type among peers. It can...
View Article
